Melanotan II: History, Mechanism and Research Explained

Arizona, the 1980s and 1990s. A team of scientists at the University of Arizona is chasing a bold idea: what if skin could tan without long hours in the sun? Darker pigment would protect it naturally, and people wouldn't have to expose themselves to the UV radiation that raises the risk of skin cancer.

That idea gave rise to the peptide Melanotan II, also known as Melanotan 2 or simply MT-II. And in the end, it did something completely different from what its creators had planned.

The Hormone That Tells the Body to Tan

When skin is exposed to the sun, the body releases a hormone called α-MSH (alpha-melanocyte-stimulating hormone). It gives the pigment cells in the skin, the melanocytes, a clear command: start making melanin. The result is a tan.

There's a catch. The body's own α-MSH breaks down very quickly, which makes it useless as a drug. So researchers at the University of Arizona began designing more stable and more potent analogs:

• First came the linear Melanotan I (now known as afamelanotide). Sawyer, Hruby, Hadley and colleagues described it in PNAS in 1980 as a "highly potent" α-MSH analog with ultralong biological activity.
• Then came the shorter and far more potent Melanotan II, with a cyclic structure. A so-called lactam bridge makes it more resistant to enzymatic breakdown, so it acts longer and at lower doses.

The Melanocortin System: The Network Few People Talk About

To understand why Melanotan II is so interesting, we need to look at the system it acts on. The melanocortin system is one of the most versatile signaling networks in the human body. According to a review by Gantz and Fong (American Journal of Physiology, 2003), it consists of:

• melanocortin peptides, all derived from a single precursor gene, POMC (proopiomelanocortin); they include α-MSH as well as ACTH, the hormone that controls the adrenal glands,
• five melanocortin receptors (MC1R to MC5R),
• two endogenous antagonists that dampen the receptors (agouti protein and AgRP),
• two accessory proteins that influence how the receptors work.

According to the same review, research has confirmed the system's role in pigmentation, inflammation and energy homeostasis. In other words: the same system that decides skin color also has a say in when we feel hungry. That is exactly what makes it such an attractive target for pharmacological research.

One Molecule, Several Locks

Each of the five receptors controls something different. Melanotan II works like a master key: it is non-selective and activates MC1R, MC3R, MC4R and MC5R. The only receptor it essentially does not act on is MC2R, the ACTH receptor in the adrenal glands.

That's why a single molecule has such a surprisingly broad range of effects.

The Study That Took a Completely Different Turn (1996)

In 1996, Life Sciences published the first pilot study of Melanotan II in humans. Three healthy male volunteers received the peptide subcutaneously for two weeks. Skin pigmentation increased on the face, the upper body and the buttocks, including areas that are not normally exposed to the sun. The authors also reported that much lower cumulative doses were needed than with the older Melanotan I.

But the researchers also observed something nobody had anticipated. Participants experienced spontaneous erections lasting 1 to 5 hours, accompanied by a peculiar stretching and yawning complex. A tanning experiment had become the starting point for one of the most fascinating lines of research into sexual function.

8 out of 10: A Result Nobody Expected

The researchers didn't let the trail go cold. In 1998, they published a double-blind, placebo-controlled crossover study in the Journal of Urology in men with psychogenic erectile dysfunction:

• 8 out of 10 men developed clinically apparent erections after receiving Melanotan II.
• Tip rigidity above 80% lasted an average of 38 minutes, compared with 3 minutes on placebo.
• Side effects (nausea, stretching and yawning, decreased appetite) were transient, and none required treatment.

A follow-up study published in Urology in 2000 tested Melanotan II in men with erectile dysfunction and organic risk factors. Here too, the peptide triggered erections far more often than placebo, and participants reported increased sexual desire. A summary paper by the same team reports that Melanotan II led to erection in 17 of 20 men, in the absence of sexual stimulation. Increased desire was reported after 68% of Melanotan II doses versus 19% of placebo doses.

The key point was where the compound acts. Classic drugs such as sildenafil enhance the response of the blood vessels. Melanotan II acts centrally, in the brain. For science, this was strong evidence that the melanocortin system plays a key role in sexuality.

Three Heirs: Drugs That Grew Out of Melanocortin Research

Melanotan II itself never went through large phase III clinical trials. But melanocortin research, in which it played a central role, paved the way for three drugs approved by the US Food and Drug Administration (FDA):

1. Bremelanotide (Vyleesi) – a direct relative of Melanotan II, developed specifically for its effect on sexual function. The FDA approved it on June 21, 2019, for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. A notable detail: according to the FDA, about 1% of patients in clinical trials developed darkening of the skin or gums. The pigmentation "signature" of the Melanotan family shows up here too.
2. Afamelanotide (Scenesse) – the original Melanotan I, the older sibling. The FDA approved it on October 8, 2019, to prevent phototoxic reactions in adults with erythropoietic protoporphyria, a rare disease in which light triggers painful reactions. It is also authorized in the European Union.
3. Setmelanotide (Imcivree) – not derived directly from Melanotan II, but an agonist of the same MC4R receptor that regulates hunger. The FDA approved it in November 2020 for obesity caused by rare genetic disorders (POMC, PCSK1 or LEPR deficiency). Its indications have since expanded, including to Bardet-Biedl syndrome.

The original quest for a safer tan thus indirectly contributed to treatments for sexual dysfunction, light sensitivity and genetic obesity.

Timeline: From a Skin Hormone to FDA-Approved Drugs

What Animal Research Has Shown

In the lab, Melanotan II has become one of the main reference tools for studying the melanocortin system:

• Appetite: A landmark study in Nature (1997) showed that Melanotan II suppresses food intake in mice via melanocortin receptors in the brain. It helped uncover the role of MC4R in regulating hunger, the very pathway that setmelanotide targets today.
• Neuroscience: A study in PLoS One (2019) found that Melanotan II reversed several autism-like features in a maternal immune activation mouse model, including improvements in social behavior.

These findings come from animal models and have not yet been confirmed in controlled human studies.

Why Melanotan II Still Matters in Research

More than thirty years after it was first created, Melanotan II remains a widely used compound in the lab. There are several reasons:

• It's a benchmark. When developing new, more selective peptides, researchers use it as a reference agonist to compare how strongly, and at which receptors, new molecules act.
• It helps untangle receptor functions. Because it activates four of the five melanocortin receptors, combining it with selective blockers lets researchers determine which receptor is responsible for which effect.
• It's stable. Its cyclic structure protects it from rapid breakdown, which makes lab work easier compared with the body's own α-MSH.
• It has an extensive literature. Decades of published data give new studies a solid foundation to build on.

Chemical Profile of Melanotan II

For research purposes, it is useful to know the compound's basic characteristics:

Frequently Asked Questions

Is Melanotan II the same as melatonin?

No. People often confuse the names, but they are completely different substances. Melatonin is a hormone that regulates sleep. Melanotan II is a synthetic analog of the hormone α-MSH.

What is the difference between Melanotan I and Melanotan II?

Melanotan I (afamelanotide) is a longer, linear peptide that primarily targets pigmentation. Melanotan II is shorter, cyclic and more potent, and it activates several melanocortin receptors at once. That's why, in addition to pigmentation, it also affects sexual function and appetite.

Is Melanotan II the same as PT-141?

No, but they are close relatives. PT-141 (bremelanotide) was derived from Melanotan II and developed with a focus on sexual function. It has been FDA-approved as Vyleesi since 2019.

Why does Melanotan II affect so many things at once?

Because it is non-selective. It activates four of the five melanocortin receptors, and each of them governs a different area: pigmentation, energy homeostasis, appetite, sexuality or glandular activity.

What is the difference between eumelanin and pheomelanin?

They are the two main types of melanin. Eumelanin is a dark brown to black pigment that tans the skin and offers better protection against UV radiation. Pheomelanin is a yellow-red pigment, typical of red hair, for example, and offers less UV protection. Activation of the MC1R receptor shifts pigment production toward eumelanin.

How does Melanotan II differ from sildenafil?

Sildenafil acts on the blood vessels of the penis and enhances a response that has already been triggered by sexual stimulation. Melanotan II acts in the brain via melanocortin receptors. That's why, in studies, it induced erections even without sexual stimulation, and participants reported increased sexual desire.

Why is Melanotan II associated with tanning?

Because it activates the MC1R receptor on melanocytes, which triggers production of the dark pigment eumelanin. In the first study in 1996, pigmentation increased even on parts of the body that are not normally exposed to the sun.

What does "research use only" mean?

The "research use only" (RUO) label means the substance is intended for laboratory and scientific research, such as receptor studies or cell models. It is not a medicine or a dietary supplement and is not intended for human use.

Why is a certificate of analysis (CoA) important for research peptides?

A certificate of analysis documents that the substance in the vial actually matches its label. It typically includes an HPLC (high-performance liquid chromatography) result showing purity and mass spectrometry (MS) data confirming the identity of the molecule. This is essential for research: without verified purity and identity, experimental results cannot be trusted.

Is Melanotan II approved as a medicine?

No. Melanotan II is not approved as a medicine by the FDA, the EMA (European Medicines Agency) or the UK's MHRA and is available exclusively as a research compound (research use only). Its relatives bremelanotide (Vyleesi) and afamelanotide (Scenesse) are approved.

Summary

Melanotan II is one of the best stories in modern pharmacology about how science often finds something other than what it was looking for. It was supposed to deliver a safer tan. Instead, it helped show that the brain controls sexual desire and hunger via melanocortin receptors, and it contributed to a path that ended with FDA-approved drugs. For scientists, it remains a valuable research tool for understanding a system that links skin, brain, appetite and sexuality.

You'll find an overview of Melanotan II and other research peptides, including their mechanisms of action, on our research compounds page: Melanotan II.

Sources

1. Sawyer TK, Sanfilippo PJ, Hruby VJ, Engel MH, Heward CB, Burnett JB, Hadley ME. "4-Norleucine, 7-D-phenylalanine-α-melanocyte-stimulating hormone: a highly potent α-melanotropin with ultralong biological activity." PNAS, 1980: pmc.ncbi.nlm.nih.gov
2. Al-Obeidi F, Castrucci AM, Hadley ME, Hruby VJ. "Potent and prolonged acting cyclic lactam analogues of α-melanotropin: design based on molecular dynamics." Journal of Medicinal Chemistry, 1989;32(12):2555–2561: experts.arizona.edu
3. Lan EL, Ugwu SO, et al. "Preformulation studies with melanotan II: a potential skin cancer chemopreventive peptide." Journal of Pharmaceutical Sciences, 1994.
4. Dorr RT, et al. "Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study." Life Sciences, 1996;58(20):1777–1784: experts.arizona.edu
5. Wessells H, et al. "Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study." Journal of Urology, 1998;160(2):389–393: pubmed.ncbi.nlm.nih.gov
6. Wessells H, Gralnek D, et al. "Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction." Urology, 2000;56:641–646: experts.arizona.edu
7. Wessells H, Levine N, Hadley ME, Dorr R, Hruby V. "Melanocortin receptor agonists, penile erection, and sexual motivation: Human studies with Melanotan II." International Journal of Impotence Research: experts.arizona.edu
8. Hadley ME, Dorr RT. "Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization." Peptides, 2006;27(4):921–930: pubmed.ncbi.nlm.nih.gov
9. Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD. "Role of melanocortinergic neurons in feeding and the agouti obesity syndrome." Nature, 1997: experts.arizona.edu
10. Minakova E, et al. "Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism." PLoS One, 2019: pmc.ncbi.nlm.nih.gov
11. Gantz I, Fong TM. "The melanocortin system." American Journal of Physiology – Endocrinology and Metabolism, 2003.
12. "Observations on the Evolution of the Melanocortin Receptor Gene Family: Distinctive Features of the Melanocortin-2 Receptor." Frontiers in Neuroscience, 2013. DOI: 10.3389/fnins.2013.00028
13. FDA approval of Vyleesi (bremelanotide), June 21, 2019: biospace.com
14. Drugs.com – Scenesse (afamelanotide) FDA approval history: drugs.com
15. EMA – Scenesse, European public assessment report (EPAR): ema.europa.eu
16. Drugs.com – Imcivree (setmelanotide) FDA approval history: drugs.com
17. Wikipedia – Melanotan II (molecular formula, molar mass, CAS number): en.wikipedia.org